BioCentury | Apr 15, 2021

Genechem’s bispecifics deal with I-Mab marks debut for a global strategy 20 years in the making

A deal with I-Mab is one of what Genechem hopes will be many to leverage an antibody discovery platform that it’s been building for the past five years. Shanghai Genechem Co. Ltd. and I-Mab...
BioCentury | Apr 10, 2021
Product Development

Bispecific constructs move beyond T cell engagers at AACR

T cell engagers have dominated the bispecific antibody scene for the past five years, but the industry is starting to branch out into next-generation structures that offer new functions and potential improvements over first-generation compounds. ...
BioCentury | Mar 4, 2021

Precision oncology readout becomes Five Prime’s denouement, driving $1.9B Amgen takeout

Roughly 19 years into Five Prime’s tortuous history, a target-validating readout in a genetically-defined subset of cancer patients spurred the biotech’s $1.9 billion buyout by Amgen, representing the latest signal of outsized interest in precision...
BioCentury | Feb 26, 2021
Distillery Therapeutics

Antibody-drug conjugate targeting CLDN6 for liver cancer

DISEASE CATEGORY: Cancer INDICATION: Liver cancer An antibody-drug conjugate targeting the tight junction protein CLDN6 could treat hepatocellular carcinoma (HCC). In patients, high tumor levels of CLDN6 protein were associated with poor overall and disease-free...
BioCentury | May 28, 2020
Distillery Therapeutics

microRNA cluster identified as targets for ischemic stroke

DISEASE CATEGORY: Neurology INDICATION: Stroke Targeting the miR-15a/miR-16-1 cluster to enhance blood-brain barrier function could treat ischemic stroke. In mice with middle cerebral artery occlusion-induced stroke, endothelial cell-specific knockout of the miR-15a/miR-16-1 cluster reduced infarct...
BioCentury | Feb 1, 2020
Company News

BioNTech’s approach to matching technologies to tumors

Though often compared to Moderna, BioNTech is not an mRNA company -- it’s a cancer company. The German biotech has amassed six different technologies in its 12-year history to address the entire continuum of solid...
BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

As drug developers try to crack the code for making CAR T cell therapies work in solid tumors, they aren’t sticking to the playbook that led to success with other modalities. BioCentury’s analysis of the...
BioCentury | Jan 4, 2020
Tools & Techniques

BioNTech tackles solid tumors by pairing CAR Ts with RNA vaccines

BioNTech is marrying two of its core technologies -- RNA therapeutics and engineered cell therapies -- to solve some of the biggest challenges of bringing CAR T cells to solid tumors. It believes that together,...
BioCentury | Nov 22, 2019
Product Development

The quiet disrupters: DNA-encoded and RNA-encoded antibodies

A new approach to streamlining biologics manufacturing could soon catch on--encoding the therapies in DNA or RNA, which enjoins the patient to produce the proteins in vivo . While the biggest upside may be the speed...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
Items per page:
1 - 10 of 106